Team build­ing. Pipeline re­vamp. For­ward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

Last year
Pharma

Af­ter a slate of small, tack-on ac­qui­si­tions, is Mer­ck ready to pull the trig­ger on a big M&A deal?

Last year
Pharma

By the num­bers: Top M&A deals, VC in­vest­ments and pacts point to a grow­ing hunger for gene ther­a­py deals

Last year
Pharma
Cell/Gene Tx

The $100M biotech club: Who's in, and what’s it take to join the top-per­form­ing group of bio­phar­mas?

Last year
Pharma

The high rollers: The top 20 block­buster bio­phar­ma deals of the past decade

Last year
Pharma

Top 20 biotech deals: 2019 deal­mak­ing gets off to a roar­ing start, build­ing on a record amount for '18

Last year
Pharma

As­traZeneca CEO So­ri­ot is over­see­ing a top ex­ec team over­haul in move to in­te­grate Med­Im­mune in a sweep­ing re­struc­tur­ing

Last year
People

Path to the top: What kind of ex­pe­ri­ence does it take to get tapped for the helm of a biotech?

Last year
People
In Focus

By the num­bers for 2018: The top 100 ven­ture play­ers in biotech — and who's been pay­ing the piper in can­cer R&D?

Last year
Venture

Scoop: GSK’s ven­ture team at SR One in talks to spin off from its big phar­ma founder, now un­der new R&D man­age­ment

Last year
Venture
Pharma

Cel­gene's top 20 up­front hits: Just how gen­er­ous was Cel­gene in deal­mak­ing? Let's re­view the records

Last year
Pharma

So what did we learn from JP­Mor­gan week? Buck­le up, it’s go­ing to be a bumpy ride

Last year
Bioregnum

‘It’s us against the world’: And George Yan­copou­los wants you to know they are beat­ing the world — big time

Last year
R&D
Pharma

The 2018 break­down on a chart-top­ping set of new drug ap­provals — and the 5 big things we learned from it

Last year
Special
Pharma

The Great Phar­ma Brex­it? An End­points News snap poll finds most life sci­ences in­sid­ers pre­dict­ing a de­ba­cle for the in­dus­try

Last year

Win­ners and losers at #ES­MO18

Last year
R&D

Ex­clu­sive: At Hal Bar­ron’s R&D group at GSK, con­sen­sus is out, lead­ers are in and watch out for an ‘in­tense dri­ve’ to spur the late-stage pipeline

Last year
People
R&D

With its rep on the line, Cel­gene's new­ly-filed safe­ty study spurs fresh wor­ries over fate of ozan­i­mod

Last year
Pharma

A go-go FDA is poised to break the all-time record on new drug ap­provals. Is this the new stan­dard for bio­phar­ma suc­cess?

Last year
Special
Pharma

Glob­al reach: The top 25 bio­phar­ma com­pa­nies in the world

Last year
Special

Genen­tech team does some cut­ting-edge work on a new class of an­tibi­otics — here's why that's im­por­tant

Last year
Bioregnum
R&D

The high-roller club in bio­phar­ma: Who’s pay­ing top-dol­lar for up­fronts? And who are the busiest play­ers at the deal ta­ble?

Last year
R&D
Pharma

Who are the most pro­duc­tive drug de­vel­op­ers in bio­phar­ma? Our top-20 list has lots of sur­pris­es

Last year
R&D
Special

Top 10 pipeline blowups, set­backs and sna­fus in H1 2018

Last year
R&D
Special
First page Previous page 12345 Next page Last page